Prothena | PRTA - Selling And Administration Expenses


Prothena reported $13.24M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Exelixis USD 123.02M 19.9M Dec/2025
Immunic USD -0.24 0.03 Sep/2024
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
MacroGenics USD 9.9M 600K Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Prothena USD 13.24M 2.67M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xoma USD 11M 2.54M Jun/2024